Q2 STOCKS TO BUY

MNK, BMY, BLUE Stocks On the Move Today

A lack of clarity over its lung cancer treatment has Bristol-Myers Squibb shares tumbling

Jun 5, 2017 at 2:09 PM
facebook X logo linkedin


It's a mixed trading session on Wall Street today, though the Nasdaq Composite (COMP) hit a record high earlier. Among names making big moves are healthcare stocks Mallinckrodt PLC (NYSE:MNK), Bristol-Myers Squibb Co (NYSE:BMY), and bluebird bio Inc (NASDAQ:BLUE). Here's a quick look at what's moving shares of MNK, BMY, and BLUE.

MNK Stock Sinks After Latest Citron Research Swipe

MNK stock is trading down 5.1% at $40.47 -- the biggest decliner on the S&P 500 Index (SPX) -- following scathing words from Citron Research. The noted short seller said the stock is "on its way to zero," after an Express Scripts executive called Mallinckrodt's H.P. Acthar Gel "vastly overpriced for the value."  In addition, the Citron report compares Mallinckrodt to Enron.

Citron initially unveiled a short MNK position in 2015, and last November accused the drugmaker of "committing securities fraud." And though the stock is down 40% since its Nov. 15 close, not a single one of the 13 analysts covering Mallinckrodt stock maintain a "sell" recommendation. This leaves the door wide open for downgrades, which could pressure MNK shares even lower.

BMY Stock Sinks After ASCO Disappointment

Bristol-Myers Squibb stock is also near the bottom of the SPX, down 4.5% at $52.51. The company presented an update for its Opdivo-Yervoy combination lung cancer treatment at the American Society of Clinical Oncology's (ASCO) annual meeting, but analysts weren't impressed, with Barclays and Credit Suisse highlighting a lack of clarity.

While BMY stock has faced increasing pressure from its 200-day moving average for most of the last 12 months, the shares are now trading below their negative 10% year-to-date mark. Against this backdrop, short-term Bristol-Myers Squibb options traders are more put-heavy now than they've been at any other point over the past year, per the stock's Schaffer's put/call open interest ratio (SOIR) of 0.90 -- an annual high.

BLUE Stock is Ripe for a Short Squeeze 

Celgene and bluebird bio gave an update on their joint multiple myeloma treatment, bb2121, at ASCO, sending BLUE shares up 10.1% to trade at $92.62. This positive price action is just more of the same for bluebird bio stock, which is boasting a nearly 51% year-to-date lead. BLUE stock is a prime candidate for a short squeeze, too, considering 19.3% of its float is sold short, or 14 times the average daily pace of trading.

 
 

“Buy This Stock Now!” - Expert Who Called 11x On TSLA

He called a rare 11x on Tesla…

But now, thanks to Elon & Trump’s new alliance…

He says there’s a new opportunity that could be 1,000x BIGGER than Tesla – and it could completely revolutionize a $23 Trillion market.

It’s trading for less than $5 per share right now…

But it won’t be under the radar for long.

Discover The 1,000x Bigger Elon Opportunity Here

GRAND SLAM COUNTDOWN

 
 

Featured Articles from Trusted Partners:

👀Learn How Dividends Create Passive Income for Life
Receive $200 Off Motley Fool Epic. The Motley Fool Epic $299 discounted offer is based on $499/year list price. Introductory promotion for new members only. Take control of your money and your portfolio with Motley Fool Epic.

💵New Income System Could Pay You $4,243 Monthly
You could collect an average of $4,243 per month starting as early as next week with a new payout system for income investors. New registrations are being accepted for investors who want to be in a position to start with their first payout next week.

🚀Easy 92% Crypto Dividends (No Coins Required)
COIN stock doesn't pay a dividend... But there's actually a new way to collect a massive dividend that's indirectly based on the stock and offers a terrific monthly income (currently yielding nearly 92% on a forward basis).

🤝Free Advisor Match with Wiseradvisor.com
Don't leave your retirement to chance! Get matched with a trusted financial expert for FREE and make the most of your tax refund. Get started now.

⚠️Dennis Quaid's #1 Warning for Americans
Here's the thing: life doesn't come with guarantees. The economy shifts, markets stumble, and years of hard work could slip through your fingers like sand. But it doesn't have to be that way for you. So request a free copy of this Gold & Silver Guide that will arrive right to your doorstep when you act now.

 

 
 

Follow us on X, Follow us on Twitter